Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Dennis J. Slamon, Patrick Neven, Stephen Chia, Peter A. Fasching, Michelino De Laurentiis, Seock-Ah Im, Katarina Petrakova, Giulia V. Bianchi, Francisco J. Esteva, Miguel Martín, Arnd Nusch, Gabe S. Sonke, Luis De la Cruz-Merino, J. Thaddeus Beck, Xavier Pivot, Manu Sondhi, Yingbo Wang, Arunava Chakravartty, Karen Rodriguez-Lorenc, Tetiana Taran, Guy Jerusalem

Open source

DOI: 10.1056/nejmoa1911149
Published: 2020-02-06
Container: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa1911149,
  title = {Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer},
  author = {Dennis J. Slamon and Patrick Neven and Stephen Chia and Peter A. Fasching and Michelino De Laurentiis and Seock-Ah Im and Katarina Petrakova and Giulia V. Bianchi and Francisco J. Esteva and Miguel Martín and Arnd Nusch and Gabe S. Sonke and Luis De la Cruz-Merino and J. Thaddeus Beck and Xavier Pivot and Manu Sondhi and Yingbo Wang and Arunava Chakravartty and Karen Rodriguez-Lorenc and Tetiana Taran and Guy Jerusalem},
  year = {2020},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa1911149},
  url = {https://doi.org/10.1056/nejmoa1911149}
}

RIS

TY  - JOUR
TI  - Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
AU  - Dennis J. Slamon
AU  - Patrick Neven
AU  - Stephen Chia
AU  - Peter A. Fasching
AU  - Michelino De Laurentiis
AU  - Seock-Ah Im
AU  - Katarina Petrakova
AU  - Giulia V. Bianchi
AU  - Francisco J. Esteva
AU  - Miguel Martín
AU  - Arnd Nusch
AU  - Gabe S. Sonke
AU  - Luis De la Cruz-Merino
AU  - J. Thaddeus Beck
AU  - Xavier Pivot
AU  - Manu Sondhi
AU  - Yingbo Wang
AU  - Arunava Chakravartty
AU  - Karen Rodriguez-Lorenc
AU  - Tetiana Taran
AU  - Guy Jerusalem
PY  - 2020
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa1911149
UR  - https://doi.org/10.1056/nejmoa1911149
ER  -

APA

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., Laurentiis, M. D., Im, S., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., Nusch, A., Sonke, G. S., Cruz-Merino, L. D. L., Beck, J. T., Pivot, X., Sondhi, M., Wang, Y., Chakravartty, A., Rodriguez-Lorenc, K., Taran, T., & Jerusalem, G. (2020). Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1911149

Source records

crossref · retrieved 2026-11-10T19:25:23.031Z